Wassila Khatir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wassila Khatir has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Bozec
Institut Universitaire de la Face et du Cou, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice, France
17 shared publications - Alizé Gouleau
Université Côte d’Azur, CNRS UMR7275, INSERM U1323, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France
17 shared publications - Anne Sudaka
Université Côte d’Azur, CNRS UMR7275, INSERM U1323, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France
17 shared publications - Axel Elaldi
VIDA Center, Computer Science and Engineering, New York University, New York, New York
17 shared publications - Aïda Meghraoui
Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, Paris, France
17 shared publications - Fabienne Anjuère
Université Côte d'Azur, CNRS UMR7275, Inserm U1323, IPMC, Valbonne, France
17 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Oxford University Press (OUP) in NAR Molecular Medicine
- Vol. 3 (2) , ugag028
MCVAE-based multi-omic anomaly detection in Fragile X Syndrome
Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by mutations in the FMR1 gene, resulting in the loss of FMRP, an RNA-binding protein regulating translation of hundreds of mRNAs. The Fmr1 knock-out mouse models this deficiency and is used to study molecular perturbations in the FXS brain. Omics analysis shows that FMRP loss disrupts coordination between transcriptomic and translatomic layers. But limited sample availability and dataset heterogeneity hinder detection of subtle, coordinated multi-omic dysregulations. To address this, we trained a Multi-Channel Variational Autoencoder (MCVAE) on wild-type samples to learn a shared latent representation of transcriptomic and translatomic modalities via cross-modal reconstruction. Testing MCVAE on Fmr1-knock-out samples revealed deviations from wild-type as anomalies, uncovering known and novel perturbations. Compared to alternative methods, MCVAE shows stronger enrichment for FMRP mRNA targets and improved genotype discriminative power in post-hoc tests. Translatomic anomalies exhibited coordinated relationships with transcriptomic anomalies, as supported by publicly available databases exploration. Moreover, these anomalies mapped to validated FMRP regulators and neurodevelopmental pathways, establishing MCVAE as a framework to uncover coordinated molecular perturbations underlying the FXS pathophysiology and guide biomarker and therapeutic target identification.
- 30 March 2026
- Published by Oxford University Press (OUP) in NAR Molecular Medicine
- Vol. 3 (2) , ugag028
Open AccessMCVAE-based multi-omic anomaly detection in Fragile X Syndrome
Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by mutations in the FMR1 gene, resulting in the loss of FMRP, an RNA-binding protein regulating translation of hundreds of mRNAs. The Fmr1 knock-out mouse models this deficiency and is used to study molecular perturbations in the FXS brain. Omics analysis shows that FMRP loss disrupts coordination between transcriptomic and translatomic layers. But limited sample availability and dataset heterogeneity hinder detection of subtle, coordinated multi-omic dysregulations. To address this, we trained a Multi-Channel Variational Autoencoder (MCVAE) on wild-type samples to learn a shared latent representation of transcriptomic and translatomic modalities via cross-modal reconstruction. Testing MCVAE on Fmr1-knock-out samples revealed deviations from wild-type as anomalies, uncovering known and novel perturbations. Compared to alternative methods, MCVAE shows stronger enrichment for FMRP mRNA targets and improved genotype discriminative power in post-hoc tests. Translatomic anomalies exhibited coordinated relationships with transcriptomic anomalies, as supported by publicly available databases exploration. Moreover, these anomalies mapped to validated FMRP regulators and neurodevelopmental pathways, establishing MCVAE as a framework to uncover coordinated molecular perturbations underlying the FXS pathophysiology and guide biomarker and therapeutic target identification.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 6. Cell densities in cSCC from different clinical situations.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 6. Cell densities in cSCC from different clinical situations.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 8. Cell densities in cSCC from primary cSCC and relapsing cSCC from paired patients.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 8. Cell densities in cSCC from primary cSCC and relapsing cSCC from paired patients.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 5. Statistical differences between the density of the immune cell subsets infiltrating NT epidermis
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 5. Statistical differences between the density of the immune cell subsets infiltrating NT epidermis
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 5. Neighborhood analysis in perilesional NT skin and in cSCC.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 5. Neighborhood analysis in perilesional NT skin and in cSCC.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 3. 39-markers IMC panel for cSCC TiME characterization
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 3. 39-markers IMC panel for cSCC TiME characterization
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 4. Comparative numbers of cells in NT epidermis and cSCC tumor islets.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 4. Comparative numbers of cells in NT epidermis and cSCC tumor islets.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 2. Sizes of cSCC and NT skin ROI
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 2. Sizes of cSCC and NT skin ROI
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 3. Abundance and density of annotated cell subsets in total NT skin and cSCC TiME.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Figure 3. Abundance and density of annotated cell subsets in total NT skin and cSCC TiME.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 4. Human antibody flow cytometry panel for phenotyping macrophages
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma
Supplementary Table 4. Human antibody flow cytometry panel for phenotyping macrophages